Who
Todd N. Smith
Director
Company insider
Files Form 4 as: Director, Latigo Biotherapeutics; Director, Pres & CEO, Assertio Holdings; President and CEO, Zyla Life Sciences; SVP & Cco, Ophthotech; EVP, Chief Commercial Officer, Horizon Pharma.
In numbers
- Trades disclosed
- 49
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $226K
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 8 Dec 2011
- Last trade
- 6 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 10 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,542 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,542 at $0.00 | filing |
| 20 May 2020filed 22 May 2020 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —603,750 | filing |
| 20 May 2020filed 22 May 2020 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —450,000 | filing |
| 20 May 2020filed 22 May 2020 | Assertio Holdings | SEC FORM 4 Code A | —644,925 | filing |
| 20 May 2020filed 21 May 2020 | Zyla Life Sciencesoption or derivative | SEC FORM 4 Code D | —241,500 | filing |
| 20 May 2020filed 21 May 2020 | Zyla Life Sciencesoption or derivative | SEC FORM 4 Code D | —180,000 | filing |
| 20 May 2020filed 21 May 2020 | Zyla Life Sciences | SEC FORM 4 Code D | —365,500 | filing |
| 4 Mar 2020filed 5 Mar 2020 | Zyla Life Sciencesoption or derivative | SEC FORM 4 Code A | —241,500 at $0.00 | filing |
| 4 Mar 2020filed 5 Mar 2020 | Zyla Life Sciences | SEC FORM 4 Code A | —165,500 at $0.00 | filing |
| 2 Jan 2020filed 2 Jan 2020 | Zyla Life Sciencesoption or derivative | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 23 Oct 2019filed 24 Oct 2019 | Zyla Life Sciences | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Jan 2015filed 6 Jan 2015 | Ophthotechoption or derivative | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 2 Jan 2015filed 6 Jan 2015 | Ophthotechoption or derivative | SEC FORM 4 Code A | —1,400 at $0.00 | filing |
| 3 Oct 2014filed 7 Oct 2014 | Ophthotechoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 19 Sep 2014filed 22 Sep 2014 | Horizon Pharma | SEC FORM 4 Code D | —54,138 | filing |
| 19 Sep 2014filed 22 Sep 2014 | Horizon Pharmaoption or derivative | SEC FORM 4 Code D | —18,955 | filing |
| 19 Sep 2014filed 22 Sep 2014 | Horizon Pharmaoption or derivative | SEC FORM 4 Code D | —21,880 | filing |
| 19 Sep 2014filed 22 Sep 2014 | Horizon Pharmaoption or derivative | SEC FORM 4 Code D | —6,699 | filing |
| 19 Sep 2014filed 22 Sep 2014 | Horizon Pharmaoption or derivative | SEC FORM 4 Code D | —61,000 | filing |
News
No headline names them, or the companies they trade most, lately.